Skip to main content

Table 1 Molecular variability and CRIM status of patients included in our study

From: Clinical manifestations in Egyptian Pompe disease patients: Molecular variability and enzyme replacement therapy (ERT) outcomes

Patient

Gender

CRIM

Molecular

1

Female

Positive

Homozygous missense mutation at codon 702 for

Arginine c.[2104 C > T]; [2104 C > T] and

(p.[Arg702Cys]; [Arg702Cys]).

2

Male

Negative

Homozygous missense mutation at codon 854 for

Arginine [2560 C > T] (p.[Arg854Ter])

3

Male

Negative

(Homozygous missense mutation at codon 335 for

Leucine c.[1064T > c]; [ 1064T > c] and

(p.[Leu335Pro]; [Leu335Pro])

4

Female

Negative

(Homozygous frameshift mutation

c.1464upc(p.(Asp489Argfs*17)).,

5

Male

Negative

Missense mutation in two variants p.Gly665,

p.Gly665Arg)

6

Male

Negative

Homozygous missense mutation at codon 854 for

Arginine [2560 C > T] (p.[Arg854Ter])

7

Female

negative

Homozygous non sense (stop) mutation in c.2560 C > T

[p.(Arg854*)]

8

Male

positive

Compound heterozygous mutation in (c,-32-13T > G) and c,1856G > A [p.Ser619Asn)].